5 results
Primary Objective To determine if 24 months of treatment with etidronate halts the progression of arterial calcification in the legs and carotid siphons. Secondary Objectives 1. To determine the effect of 24 months of treatment with etidronate on…
The primary objective for this study is to compare the safety, tolerability and analgesic efficacy of ABT-110 administered subcutaneously (SC) once every 8 weeks (q8w) for a total of 2 doses to placebo in subjects with pain due to osteoarthritis (OA…
The objective is to determine whether etidronate can halt or attenuate disease progression in patients with Fahr*s disease or syndrome.
Primary objective:To assess the efficacy of PXT3003 compared to Placebo on the disability measured by the ONLS score in CMT1A patients treated for 15 months.Secondary objectives:- To assess the efficacy of PXT3003 compared to Placebo on clinical and…
Primary:To evaluate the efficacy of treatment with PXT3003 (a fixed-dose combination of (RS)-baclofen, naltrexone hydrochloride, and D-sorbitol) compared to placebo in subjects with CMT1A.Secondary: To evaluate the safety and tolerability of PXT3003…